- Home
- MARPS vs SILO Comparison
MARPS vs SILO Comparison
Compare MARPS & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- SILO
- Stock Information
- Founded
- MARPS 1956
- SILO 2010
- Country
- MARPS United States
- SILO United States
- Employees
- MARPS N/A
- SILO N/A
- Industry
- MARPS Oil & Gas Production
- SILO Apparel
- Sector
- MARPS Energy
- SILO Consumer Discretionary
- Exchange
- MARPS Nasdaq
- SILO Nasdaq
- Market Cap
- MARPS 7.8M
- SILO 8.8M
- IPO Year
- MARPS N/A
- SILO N/A
- Fundamental
- Price
- MARPS $3.90
- SILO $1.16
- Analyst Decision
- MARPS
- SILO
- Analyst Count
- MARPS 0
- SILO 0
- Target Price
- MARPS N/A
- SILO N/A
- AVG Volume (30 Days)
- MARPS 3.3K
- SILO 92.8K
- Earning Date
- MARPS 01-01-0001
- SILO 05-12-2025
- Dividend Yield
- MARPS 8.49%
- SILO N/A
- EPS Growth
- MARPS N/A
- SILO N/A
- EPS
- MARPS 0.30
- SILO N/A
- Revenue
- MARPS $945,496.00
- SILO $72,102.00
- Revenue This Year
- MARPS N/A
- SILO $1.86
- Revenue Next Year
- MARPS N/A
- SILO N/A
- P/E Ratio
- MARPS $12.98
- SILO N/A
- Revenue Growth
- MARPS N/A
- SILO N/A
- 52 Week Low
- MARPS $3.76
- SILO $0.77
- 52 Week High
- MARPS $5.20
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- MARPS 50.35
- SILO 47.25
- Support Level
- MARPS $3.81
- SILO $0.99
- Resistance Level
- MARPS $3.92
- SILO $1.19
- Average True Range (ATR)
- MARPS 0.06
- SILO 0.08
- MACD
- MARPS 0.00
- SILO 0.02
- Stochastic Oscillator
- MARPS 68.75
- SILO 75.00
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.